Sharechat Logo

NZ Super Fund's Matt Whineray to be acting CEO from mid-March

Thursday 15th February 2018

Text too small?

New Zealand Superannuation Fund chief investment officer Matt Whineray will take over as acting chief executive when Adrian Orr leaves to take up his new role as governor of the Reserve Bank in March.

Last month, the fund said it aimed to replace Orr by mid-May and issued a tender document to find a recruitment agency to find that person. Applications for the recruitment job "are still being reviewed", before a global search kicks off in an appointment process expected to "take a number of months", it said.   

Whineray will start the acting CEO role from mid-March and general manager portfolio completion Mark Fennell will become acting chief investment officer for the duration of the recruitment process.

The new chief executive will oversee the $37.9 billion fund, which has had an annual 10.5 percent average annual rate of return since inception, before tax and after costs, and a workforce of approximately 140 people, including 55 investment professionals. While 86 percent of the fund is invested globally, it has $5 billion invested in New Zealand. 

Orr's total pay package was $1.22 million in the 2017 June year, up from $1.06 million in 2016. 

(BusinessDesk)



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

NZK - Blue Endeavour Pilot Farm and Wellboat Update
TRU - FY 31 March 2026 Revenue and Results Guidance Achieved
FBU - Fletcher Building sale of Fletcher Reinforcing and Wire
April 28th Morning Report
RYM - Ryman Healthcare appoints new independent director
ikeGPS 4Q FY26 and Full Year FY26 Performance Update
HGH - Heartland trading update
CVT - Comvita Rights Offer Opens
GNE - FY26 Q3 Performance Report and Updated Guidance
April 23rd Morning Report